UA88508U - Method for correcting impaired purine metabolism in patients with arterial hypertension and metabolic syndrome - Google Patents

Abstract

A method for correcting the impaired purine metabolism in the patients with arterial hypertension and metabolic syndrome comprises the biochemical examination of the blood serum for measuring the concentration of uric acid (UA). In the setting of the background antihypertensive therapy, hypouricemic drugs (HUDs) are prescribed. In addition, the blood concentrations of C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) are measured. UA content is also determined in the urine. HUDs are prescribed differentially based on the detected type of the purine metabolism. In cases of the impaired purine metabolism associated with hyperuricemia when UA content is above the normal value only in blood serum, HUDs with uricodepressive activity is prescribed, for example Allopurinol at the prophylactic dose. In cases of the impaired purine metabolism associated with combined hyperuricemia and hyperuricosuria when UA content is above the normal value both in blood serum and in urine, the fixed low dose of the combined HUDs with uricodepressive and uricosuric activities is prescribed, for example Allomaron. When CRP concentration is increased at least by 15 % and VEGF concentration is increased at least by 25 %, the treatment is supplemented with the herbal anti-inflammatory drug such as Homvio-Reuman. HUDs are prescribed at the therapeutically effective and safe doses for 12 weeks. When the normalization of proinflammatory and proangiogenic factors is not sufficient, the treatment course for extra 6 weeks is provided.